VectorY to Present at the ASGCT Annual Meeting in May 2023

Amsterdam, The Netherlands, 1 May 2023 – VectorY Therapeutics, a biotech company developing disease-modifying vectorized antibody therapies for the treatment of neurodegenerative diseases, today announces presentations during the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) during the month of May.

26th ASGCT Annual Meeting, May 16-20, Los Angeles, CA

Poster title: VecTabs Target Oxidized Phosphatidylcholine for Treating Amyotrophic Lateral Sclerosis (#558)
Presenter: Raygene Martier, Intellectual Property Manager
Date and time: May 17, 12:00 PM PT

Poster title: The VeCap® Platform: Structurally Engineered Tissue Specific AAV Capsids (#1092)
Presenter: Giulia De Sabbata, Principal Scientist Vector Technologies
Date and time: May 18, 12:00 PM PT

About VectorY

VectorY is on a mission to provide people with neurodegenerative diseases a longer, better life by creating transformative vectorized antibody treatments. Our platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS. Unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing and neuroscience drives the rapid development of much needed disease-modifying therapies for neurodegenerative diseases such as ALS and Huntington’s disease. For more information, see www.vectorytx.com.